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Summary Irinotecan (CPT-11) is a semisynthetic camptothecin derivative with a broad spectrum of anti-tumour activity. Carboxylesterase
(CE) catalyses the conversion of CPT-11 to SN-38 (7-ethyl-10-hydroxycamptothecin), the active form of CPT-11. The antiproliferative effects
of CPT-11 and SN-38, CE-activity and topoisomerase protein expression were investigated in five human small-cell lung cancer (SCLC) cell
lines and four human non-small-cell lung cancer (NSCLC) cell lines. Antiproliferative activity, expressed as IC50 values, was determined using
the MTT assay. CPT-11 was significantly more active in SCLC than in NSCLC cell lines (P = 0.0036), whereas no significant difference
between histological types was observed with SN-38. A significant correlation (r2 = 0.52, P = 0.028) was observed between CE activity and
chemosensitivity to CPT-11 but not to SN-38, and significantly higher CE activity was observed in SCLC compared with NSCLC cell lines
(P = 0.025). Western blotting experiments showed topoisomerase protein expressions within a factor of 2, and a granular nuclear staining
was detectable in all cell lines by immunocytochemistry of cytospins. No correlation was observed between protein expression and sensitivity
to CPT-11 or SN-38. Cellular and medium concentrations of CPT-11 and SN-38 were measured by high-performance liquid chromatography
(HPLC) in one SCLC cell line with high CE activity and high sensitivity to CPT-11, and one NSCLC cell line with low sensitivity to CPT-1i1 and
CE activity. Intracellular concentrations of CPT-11 and SN-38 were higher in the SCLC cell line, and this was associated with an increase in
cellular uptake of CPT-11 compared with the medium, and an increased intracellular formation of SN-38. In conclusion, CE activity appears to
be associated with higher sensitivity to CPT-1i1 in human lung cancer cell lines and may partly explain the difference in the in vitro sensitivity
to CPT-11 between SCLC and NSCLC cells. The assessment of CE activity in clinical material of lung cancer patients undergoing treatment
with CPT-11 may be warranted. However, other mechanisms may influence sensitivity to CPT-11, possibly including drug transport.
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Camptothecin is a potent anti-cancer agent and specific inhibitor
of topoisomerase I. Unfortunately, the clinical development of
camptothecin was halted because of its poor water solubility and
unpredictable severe side-effects observed in early clinical studies
(Potmesil, 1994). Irinotecan (CPT-I1) is a water-soluble derivative
of camptothecin, developed in Japan (Potmesil, 1994) which is
converted into the active metabolite SN-38 by a carboxylesterase
(CE), which is present in the liver and serum (Kaneda et al, 1990).
Camptothecins stabilize the cleavable complex formed between
DNA, enzyme and drug; consequently, the cleavable complex
impedes the religation of transient DNA single-strand breaks and
blocks the replication fork, eventually leading to lethal double-
strand breaks (Liu, 1989).
Activity of CPT-11 has been reported in several malignancies
(Slichenmyer et al, 1993; Potmesil, 1994), and remarkable effi-
cacy has been observed in tumours that are poorly responsive to
conventional chemotherapy, such as non-small-cell lung cancer
(NSCLC) and colon cancer. The mechanisms responsible for the
higher sensitivity to chemotherapy of small-cell lung cancer
(SCLC) compared with NSCLC are not well understood. A higher
expression and activity of topoisomerase II were observed in
SCLC than in NSCLC cell lines, which may partly explain the
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higher response of the former to the topoisomerase II inhibitors
etoposide and doxorubicin (Kasahara et al, 1992). Furthermore, a
lower etoposide uptake in NSCLC cells was also reported. CPT-11
as a single agent achieved response rates of 12-34% in previously
untreated NSCLC patients, and response rates of 43-54% when
combined with cisplatin. Response rates of 23-47% were
observed when CPT-11 was administered as a single agent to
pretreated SCLC patients and response rates of 58-86% when
combined with cisplatin (Giaccone, 1996). Lower expression of
the target enzyme topoisomerase I, mutations of the gene and
reduced metabolic conversion (for CPT-11 only) have been
suggested to be responsible for drug resistance to this new class of
anti-cancer agents (Slichenmyer et al, 1993; Potmesil, 1994). In
this study, we attempted to identify the determinants of the
differential sensitivity oflung cancer cells to CPT-I1.
MATERIALS AND METHODS
Chemicals and drugs
CPT-11 and SN-38 were kindly provided by Yakult Honsha
(Tokyo, Japan). Both compounds were solubilized in dimethyl
sulphoxide and stored, protected from light, at 4°C. Para-nitro-
phenylacetate (p-NPA) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were from Sigma Chemical
(Zwijndrecht, NL). All otherchemicals were ofstandard analytical
quality and were commercially available.
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Cell lines
The origin and maintenance of all human lung cancer cell lines
have been described previously (Zijlstra et al, 1987; Carmichael et
al, 1988; Kuiper et al, 1990). The NSCLC cell lines were cultured
in Nunc flasks (Roskilde, Denmark) as monolayers, whereas the
SCLC cells grew as floating clusters. The culture medium was
RPMI medium (Flow Labs, Irvine, UK) supplemented with 10%
fetal calf serum (FCS, Gibco, Paisley, UK) and 1 mM L-glutamine,
except for the NSCLC cell line SW-1573, which was cultured in
Dulbecco's modified Eagle medium (DMEM, Flow Labs) supple-
mented with 10% FCS. Cell lines were maintained in a 5% carbon
dioxide incubator at 37°C. The resistant cell line GLC4/ADR was
cultured in the presence of doxorubicin until 7-14 days before
experiments. All cell lines were free from Mycoplasma as tested
with the mycoplasma T.C. rapid detection system with a 3H-
labelled DNA probe from Gen-probe (San Diego, CA, USA).
Antiproliferative activity
Drug effects on exponentially growing cells were determined
using the semiautomated MTT assay (Carmichael et al, 1988).
Drugs were diluted in culture medium and added to the cultures
24 h after cell seeding. Drug exposure time was for 96 h, after
which 0.1 mg per well of MTT was added, and the plates were
further incubated for 4 h. Supernatants were carefully removed,
and formazan crystals were dissolved in 150,l of dimethyl
sulphoxide. The optical density was measured at 540 nm using a
Titertek microplate reader (Multiscan MCC/340, Flow, UK).
Antiproliferative activities of CPT-11 and SN-38 were expressed
as drug concentrations that induced 50% of growth inhibition
compared with growth ofuntreated control (IC50). The IC50 values
were the means of at least three independent experiments, each
performed in replicates of six.
Carboxylesterase activity
Carboxylesterase (CE) activity was assessed in all cell lines, culture
medium and blood of healthy volunteers by measuring the hydro-
lysis ofpNPA to para-nitrophenol catalysed by CE, as described by
Tsuji et al (1991). Briefly, cells were harvested, counted and washed
twice with cold phosphate-buffered saline (PBS); cell pellets were
then solubilized in 20 mm cold Tris-HCl, pH 7.5, and placed on ice
for 1 h. After centrifugation at 14 000 r.p.m. for 30 min at 4°C,
serial dilutions of the supernatants were pipetted into a 96-well
microtitre plate (180gl per well total volume). After addition of
20 ,ul of 10 mm pNPA to all wells, plates were incubated for 10 min
at 37°C. Formation of para-nitrophenol, a yellow solution, was
measured directly in a microplate reader (Biorad 3550 UV) at a
wavelength of 405 nm. The enzyme activities, expressed in units
(1 unit is the concentration ofpNPA [M] hydrolysed per min perone
million cells), were the means offour independent experiments.
Immunocytochemistry and Western blotting
The mouse monoclonal antibody Topol/6G5, kindly provided by
Dr G Astaldi Ricotti (Pavia, Italy), was used to study topoiso-
merase I protein expression in cell cytospins, and staining was
performed as previously described (Giaccone et al, 1995). Western
blotting was performed according to the enhanced chemilumines-
cence (ECL) protocol by Amersham (Buckinghamshire, UK) with
the monoclonal antibody diluted 1:100 (Whitehead et al, 1979), as
described previously (Pizao et al, 1994). In short, proteins were
extracted from isolated nuclei and the protein samples were loaded
on an acrylamide gel and run for 1.5 h at 100 V. Proteins were
blotted on an Hybond ECL nitrocellulose filter (Amersham) and
incubated with Topol/6G5 for 1 h at room temperature, washed
and incubated with a horseradish peroxidase-labelled anti-mouse
IgG (Dako, Glosstrup, Denmark) for 1 h. After washing, the
membrane was incubated with an ECL detection reagent
(Amersham) for 1 min. Bands were visualized on Hyperfilm ECL
(Amersham) by autoradiography.
HPLC analysis of CPT-11 and SN-38
For further studies, we selected the NCI-H322 (NSCLC) and NCI-
HI87 (SCLC) cell lines, which displayed the highest difference in
sensitivity to CPT-11 and CE activity. Cell lines were grown in
flasks and a drug incubation period of24 h to 2 ,UM ofCPT-11 was
chosen to assure complete drug uptake into the cells and before
massive cell kill. After exposure, cells were harvested, counted
and washed twice with cold PBS. Cell pellets were extracted with
cold acetonitrile/methanol (1:1) for 10 min. After centrifugation
(1 min, 1°C, 13 500g) 100 tl of the supernatant was added to
300 gl of 50 mm ammonium acetate/5 mm tetrabutylammoni-
umdihydrogenphosphate (TBAP) (pH 6.6). For each cell line, this
experiment was performed six times.
Table 1 Cytotoxicity of CPT-11 and SN-38, carboxylesterase (CE) activity and topoisomerase protein expression of human lung cancer cell lines
Cell line Tumour IC50CPT-11 (M) lC50SN-38 (M) Ratio CE activity Relative
type (mean + s.d.) (mean ± s.d.) IC50 U (+ s.d.)a Topol expressionb
NCI-H322 NSCLC 2.1 (±1.1) x 10-6 1.1 (±0.9)x 10-8 191 0.56(0.28) x 10-8 0.97
NCI-H460 NSCLC 3.0 (0.9) x 10-6 2.1 (+0.1) x 10-9 1429 0.44 (0.12) x 10-8 0.69
NCI-H522 NSCLC 2.3 (+ 1.6) x 10-6 1.1 (+ 0.5) x 10-10 20909 2.45 (± 0.50) x 10-8 0.47
SW1573 NSCLC 2.1 (+0.4) x 10-6 1.3 (0.8) x 10-10 16154 0.54(0.43) x 108 0.58
NCI-H69 SCLC-cc 8.5 (± 6.5) x 10-7 2.7 (± 3.3) x 10-9 314 2.76 (± 0.59) x 104 0.87
NCI-H187 SCLC-cc 3.5 (± 1.3) x 10-7 2.4 (± 2.5) x 10- 1458 3.06 (± 0.63) x 104 0.80
GLC4 SCLC-cc 1.5 (±0.5) x 10-6 5.1 (+7.0) x 10-10 2941 1.91 (+0.90) x 10-6 0.95
GLC4/ADR SCLC-vc 1.5 (0.4) x 10-6 2.1 (+1.2) x1O0-' 7143 2.31 (+1.62) x 1-8 1.00
NCI-N417 SCLC-vc 4.5 (± 2.1) x 10-7 0.8 (± 0.5) x 10-10 8065 1.96 (± 0.94) x 104 0.75
aOne unit = M pNPA (mean ± s.d.) min-' 10-6 cells (n = 4). bProtein expression was assessed by Western blotting, GLC4/ADR, the cell line with the highest
expression, was set at 1.00. Densitometry was performed across the entire molecular weight region. cSCLC-c and SCLC-v are classic and variant types of
small-cell lung cancer cell lines respectively.
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Extracellular drug concentrations were studied by extracting
200 gl of the culture medium with 300,l of cold aceto-
nitrile/methanol (1:1) followed by centrifugation for 1 min at 1°C
at 13 500g; 250 ,ul of the supernatant was then added to 750 ,tl
of 50 mm ammonium acetate/5 mm TBAP (pH 6.6). Fifty
microlitres of the TBAP-containing solutions were injected into a
high-performance liquid chromatography (HPLC) system
provided with two Prodigy 5 ODS2 columns of 150 x 3.2 mm
(Phenomenex, Bester, Amstelveen, The Netherlands), a mobile
phase consisting of an ammonium acetate buffer, TBAP, methanol
and acetonitrile and two fluorescence detectors (kex = 385 nm and
ken=450nmforCPT-ll;kex=385nm andkem = 530 nm for SN-
38). The lower limit of quantification (LLQ) was 0.5 nm for CPT-
11 (lactone and carboxylate) and 1.0 nm for SN-38 (lactone and
carboxylate). The between-day precision was 7.2%, 5.7%, 9.9%
and 7.8% for CPT-11 carboxylate, CPT-11 lactone, SN-38
carboxylate and SN-38 lactone at a concentration of 3 nm and
5.6%, 5.5%, 7.8% and 5.5% for the same four compounds at a
concentration of 150, 75, 20 and 45 nm respectively.
RESULTS
Antiproliferative activities of CPT-11 and SN-38
The antiproliferative activities of CPT-11 and SN-38 are summa-
rized in Table 1: a wide range of sensitivities was found between
CPT-11 and SN-38 in the different cell lines. A significantly higher
activity of CPT-11 was observed in SCLC [mean IC50 (± s.d.) =
0.93 (+ 0.55) x 106 M] than in NSCLC [mean IC50 (+ s.d.) = 2.38
(± 1.54) x 106 M] (P = 0.0036). All cell lines displayed a much
higher sensitivity to SN-38 than to CPT-11, the ratios between
CPT-11 and SN-38 cytotoxicities varying within approximately
4 logs. The cytotoxicity to SN-38 was not influenced by different
cell type (P = 0.40). The sensitivity of the doxorubicin-resistant
SCLC cell line GLC4/ADR to CPT-11 and SN-38 was similar to
that of the parent cell line, indicating no cross-resistance between
the topoisomerase II inhibitor doxorubicin and the topoisomerase I
inhibitors CPT- II and SN-38.
Carboxylesterase activity
A significant correlation was found between the sensitivity to
CPT-11 and the CE activity of the cell lines (r2 = 0.52, P = 0.028)
(Figure 1). When CE activity was expressed as mU mg-' ofprotein
(Jansen et al, 1997), similar results were obtained (not shown).
Similar to the CPT-11 cytotoxicity, the CE activity detected in
SCLC cell lines was significantly higher than that of the NSCLC
cell lines (P = 0.025) (Table 1). This difference could not be
explained by different processing of the cell lines, such as the use
of trypsin for the isolation of cells growing as monolayers
(Heymann and Mentlein, 1981) or by a difference in the protein
contents of the cell lines (not shown). We also measured the CE
activity in the culture medium and human serum, which were 5.8%
and 5.1% ofthat of the cell lines respectively.
Topoisomerase I protein expression
A granular nuclear staining, as has been described before
(Giaccone et al, 1995), was detectable in all cell lines by immuno-
cytochemistry of cytospins (not shown). Western blotting of
protein extracts identified the two topoisomerase I bands (100 and
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Figure 1 Correlation between IC50 of CPT-11 and CE activity (units in M
pNPA x 10-8 min-' 10- cells). A significant correlation was found (P= 0.028)
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Figure 2 Western blot analysis of Topoisomerase protein expression
in SCLC and NSCLC cell lines. Two forms of topoisomerase are visible
(100 kDa and 67 kDa), and an intermediate band in some samples
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Figure 3 Mean intracellular concentration of CPT-11 and SN-38,
carboxylate and lactone forms, in the two human lung cancer cell lines NCI-
H187 (SCLC) and NCI-H322 (NSCLC). Experiments were repeated five
times; * is under the lower limit of quantification. All differences in CPT-11
uptake are significantly in favour of NCI-H187 cells
67 kDa) in all cell lines, and an additional intermediate molecular
weight band, probably a product ofdegradation, in at least two cell
lines. Densitometry, performed across the whole molecular weight
area, revealed that the total amounts were within a factor oftwo in
the different cell lines (Figure 2 and Table 1). The topoisomerase I
protein expression was not correlated with the sensitivity to CPT-
1, SN-38 or with CE activity.
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Table 2 Intra- and extra-cellular concentrations of CPT-11 and SN-38 in SCLC cell line NCI-H187 (n = 5) and NSCLC cell line NCI-H322 (n = 5) after 24 h of
drug exposure
Total drug concentration (nM)
Location Drug NCI-H187 NCI-H322 P-value
Cell homogenate CPT-11 carboxylate 1074 ± 215 400 + 130 0.002
CPT-11 lactone 3425 +797 1707 + 330 0.006
SN-38 carboxylate ND ND
SN-38 lactone 2.8 ± 0.6 ND
Total 4503 +645 2107 ± 287 0.005
Medium CPT-11 carboxylate 1101 ± 55 982 + 60 0.018
CPT-11 lactone 632 + 121 710 ± 69 0.29
SN-38 carboxylate ND ND
SN-38 lactone ND ND
Total 1733 + 88 1692 ± 70 0.45
Ratio of totals 2.6 1.3
ND, not detectable, i.e. below the lower limit of quantification.
Intra-and extracellular concentrations of SN-38 and
CPT-11
Concentrations of CPT-11 and SN-38 (carboxylate and lactone
forms) were measured in the two cell lines NCI-H187 and NCI-
H322 (Figure 3). In both cell lines, the concentration ofthe active
lactone form ofCPT- 11 was higher than the carboxylate form. The
total level ofCPT-11 found in the cell line NCI-H187 was approx-
imately two times higher than that of NCI-H322, indicating a
higher CPT-11 uptake during the 24 h incubation time in the SCLC
cell line NCI-H187 than in the NSCLC cell line NCI-H322. Both
forms (carboxylate and lactone) were also higher in NCI-H187
than in NCI-H322. Total SN-38 and its lactone form were
detectable in the sensitive cell line NCI-H187 but were under the
detection limit of the method in the more resistant cell line NCI-
H322. SN-38 carboxylate was under the detection limit in both cell
lines. The intra- and extra-cellular concentrations of CPT-11 and
SN-38 at the end ofthe 24-h drug exposure are reported in Table 2.
Slightly but significantly higher cell pellet concentrations
compared with the medium were found in the cell line NCI-H322
(P = 0.025), and this difference was even more striking in NCI-
H187 cells, in which the cellular concentration was 2.6 times
higher than that in the medium (P = 0.002), which might be an
indication of active transport of CPT- 11 into the cells. Neither the
lactone nor the carboxylate of SN-38 were detectable in the
medium. SN-38 was only detectable as the lactone in the cell pellet
of the cell line NCI-H187, which might explain the difference in
drug sensitivity between the cell lines and may also indicate that
SN-38 is formed intracellularly.
DISCUSSION
A striking difference in sensitivity to most cytotoxic drugs exists
between histological types of lung cancer, SCLC being far more
sensitive than NSCLC. The nature of this different sensitivity is
poorly understood. CPT-11 has recently shown promising results in
clinical trials in lung cancer patients, response rates in SCLC being
higher than in NSCLC (Giaccone, 1996). Interestingly, in our study,
the SCLC cell lines were significantly more sensitive to CPT-1
than the NSCLC cell lines. The large difference in antiproliferative
activity between CPT-11 and the active metabolite SN-38 in
our panel of human lung cancer cell lines is consistent with
previous findings (Kaneda et al, 1990; Kawato et al, 1991; Jansen
etal, 1997).
For the topoisomerase I inhibitor CPT-11, the reduced intra-
cellular conversion of CPT-11 to its active metabolite SN-38 was
reported to be the main cause of drug resistance in two human
cancer cell lines (Kanzawa et al, 1990; Niimi et al, 1992) and in a
gastric tumour xenograft line (Nagai et al, 1995). In these cell
lines, a decreased CE activity caused a decreased intracellular
conversion of CPT-11 to its active metabolite, resulting in relative
resistance. In our study, SCLC cell lines had significantly higher
levels of CE activity than NSCLC lines. The correlation between
high endogenous CE activity and higher sensitivity to CPT-II
suggests the use of CE activity as a determinant of CPT-11 effi-
cacy. However, we were unable to confirm this association in
SCLC or NSCLC cell lines separately, probably because of the
small number ofcell lines (not shown). In a recent study, we could
not find a correlation between the CE activity and sensitivity to
CPT-l1 of human colon cancer cell lines (Jansen et al, 1997),
suggesting the existence ofdifferences between tumour cell types.
CE activities in human tumours vary widely, as reported in 18
different tumour types: interestingly, SCLC tumour tissues were
found among those displaying the highest CE activity (Chen et al,
1994). Determination of CE activity may pose some technical
problems for application in human tumours, as a study in rats and
mice showed that endogenous carboxylesterase enzymes are
present in several normal tissues, including plasma, intestinal
mucosa and liver (Tsuji et al, 1991; Jansen et al, 1997). In our
study, however, only a low CE activity was found in human serum
compared with that found in the human lung cancer cell lines.
Because only a small percentage (< 10%) of CPT-11 is
converted into SN-38 after administration to patients (Rowinsky et
al, 1994), targeting the CE gene to tumour cells might offer a new
treatment strategy for prodrugs that are activated by CE (Senter et
al, 1996). Rat serum carboxylesterase was reported to enhance
the cytotoxic activity of paclitaxel-2-ethylcarbonate and CPT-11,
prodrugs ofpaclitaxel and SN-38 respectively (Senter et al, 1996).
Decreased expression of the topoisomerase I gene or reduced
activity of the enzyme is a common cause ofdecreased sensitivity
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to topoisomerase I inhibitors in drug-resistant in vitro selected cell
lines (Gupta et al, 1995). In our study, the topoisomerase I protein
level determined by immunohistochemistry and by Western blot-
ting did not predict sensitivity to CPT-11 or SN-38. However, we
recently observed a correlation between topoisomerase I enzyme
activity and sensitivity to SN-38 in five colon cancer cell lines
(Jansen et al, 1997). In this study, no correlation was observed
between topoisomerase I mRNA expression and sensitivity to
CPT-11. Previous studies of unselected human lung cancer cell
lines and cell lines of other origin have shown that sensitivity to
camptothecin was not correlated to the mRNA expression of the
gene, with cell doubling time or percentage ofS-phase cell popula-
tion (Giaccone et al, 1992; Perego et al, 1994). In another study of
seven human colon cancer cell lines, the activity of camptothecin
was not correlated with topoisomerase I mRNA or protein expres-
sion, drug uptake or percentage ofcells in S-phase, but a log-linear
correlation was observed between camptothecin-induced cleav-
able complexes and growth inhibition (Goldwasser et al, 1995).
In our study, we performed assays that may eventually be
applied to patients' samples; we did not perform activity assays or
cleavable complex studies, as these require large numbers of cells
and are not feasible on small biopsies, which is often the only
material available from SCLC patients. Furthermore, in a recent
report, a weak but significant linear relationship (r2 = 0.2,
P < 0.0094) was observed between topoisomerase I activities and
protein expression in lung cancer samples (Savaraj et al, 1997).
In the two lung cancer cell lines displaying a large difference in
chemosensitivity, we identified a significant difference in CPT- 11
uptake, suggesting the involvement of a transport mechanism
affecting the activity of this drug. Moreover, in the more sensitive
cell line, a higher intracellular concentration of the active metabo-
lite SN-38 was found, in agreement with the higher CE activity
detected. These findings would indicate the presence of at least
two different mechanisms of sensitivity to CPT-11: one dependent
on an active drug transport and a second one dependent on meta-
bolic activation. A higher intracellular concentration ofSN-38 was
also described in the human non-small-cell lung cancer cell line
PC-7 than in its CPT-l1 -resistant variant, but no difference in drug
accumulation was found in this study (Kanzawa et al, 1990).
Camptothecins are weak substrates of transmembrane trans-
porter proteins such as P-glycoprotein or the multidrug resistance-
associated protein MRP. However, the camptothecin derivative
topotecan has been described to be weakly transported by P-glyco-
protein (Chen et al, 1991; Mattern et al, 1993), more than CPT-11.
P-glycoprotein is generally undetectable in unselected human lung
cancer cell lines (Lai et al, 1989) whereas MRP was expressed in
all cell lines examined (Giaccone et al, 1996).
In selected cell lines expressing P-glycoprotein, this transporter
appeared to influence the sensitivity to CPT-11 and SN-38 in vitro,
but this had little influence on the activity of the drugs in
xenografts (Jansen et al, 1998). Moreover, MRP expression did not
appear to affect the activity of CPT- 11 or SN-38. In the present
study, the doxorubicin-resistant multidrug-resistant cell line
GLC4/ADR was as sensitive to CPT-11 and SN-38 as the parent
cell line GLC4. As GLC4/ADR overexpresses MRP (Zaman et al,
1993), this is a further indication that CPT-11 is also not a substrate
ofthis transport protein. Recently, homologues of MRP have been
identified, and their involvement in drug resistance needs further
investigation (Kool et al, 1997).
Altered accumulation of camptothecins has been described in
the absence of MDR1 expression: in CHO cells resistant to
camptothecin, a decreased accumulation of the drug was observed,
compared with the parent cell line (Chang et al, 1992). Furthermore,
in MCF7/MX, a mitoxantrone-resistant breast cancer cell line,
cross-resistance was observed to topotecan, CPT-11, SN-38 and
9-aminocamptothecin, but only slightly to camptothecin (Yang et al,
1995). Interestingly, this cell line displayed a decrease in accumula-
tion for topotecan and camptothecin, in the absence of P-glyco-
protein expression and levels of expression of MRP similar to the
parent cell line. A reduced stimulation of the cleavable complex by
topotecan was also reported, without a difference in topoisomerase
gene expression.
Cross-resistance in general occurs between topoisomerase I
inhibitors, but variable degrees may exist and different mecha-
nisms of drug resistance may be involved. For example, the
activity ofthe novel indolocarbazole substrate NB-506 appeared to
be reduced by a defect in accumulation in resistant cell lines,
whereas camptothecin was not affected (Kanzawa et al, 1995).
In conclusion, high CE activity in human lung cancer cell lines
was associated with a higher cytotoxicity of CPT-II and was
greater in SCLC than in NSCLC cells. The use of the CE activity
assay may be warranted in the prospective assessment of tumour
response of lung cancer patients to CPT-I11. However, the mecha-
nisms ofresistance to CPT-11 and other topoisomerase I inhibitors
are likely to be more complex and, among others, include alter-
ations in cellular transport. Further investigations are necessary to
elucidate the nature and the relevance ofthis transport mechanism.
REFERENCES
Carmichael J, Mitchell JB, Degraff WG. Gamson J. Gazdar AF, Johnson BE,
Glatstein E and Minna JD (1988) Chemosensitivity testing of human lung
cancer cell lines using the MTT assay. BrJ Caincer 57: 540-547
Chang J-Y. Dethlefsen LA, Zhou B-S and Cheng Y-C (1992) Characterization of
camptothecin-resistant chinese hamster lung cells. Biochemii Pharma7l(icol 43:
2443-2452
Chen AY, Potmesil M, Wall ME, Wani MC and Liu LF (I1991) Camptothein
overcomes MDRI-mediated resistance in human KB carcinoma cells.
Cauncer Res 51: 6039-6044
Chen S-F. Rothenberg ML, Clark G, Degen D? Wajima M, Barton D and
Von Hoff DD ( 1994) Human tumor carboxylesterase activity correlates
with CPT-1 I cytotoxicity int vitro (abstract). ProcAnt Assoc Coatcer Res 35:
365
Giaccone G (I1996) New drugs for the management of lung cancer. B-J Hosp Med
55: 634-638
Giaccone G, Gazdar AF. Beck H. Zunino F and Capranico G (1992) Multidrug
sensitivity phenotype ofhuman lung cancer cells associated with topoisomerase
II expression. Concer Res 52: 1666-1674
Giaccone G, Van Ark-Otte J. Scagliotti G. Capranico G. Van der Valk P, Rubio G,
Lopez R, Zunino F. Walboomers J and Pinedo HM (1995). Differential
expression of DNA topoisomerases in non-small cell lung cancer and normal
lung. Biochim Biophys Acta 1264: 337-346
Giaccone G, Van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans
AMC, Flens MJ, Scheper RJ and Pinedo HM ( 1996) MRP is frequently
expressed in human lung cancer cell lines, in non-small cell lung cancer and
normal lung. I,tt J Ccitcer 66: 768-771
Goldwasser F, Bae 1, Valenti M, Torres K and Pommier Y (1995) Topoisomerase 1-
related parameters and camptothecin activity in the colon carcinomiia cell lines
from the National Cancer Institute anticancer screen. CanicerRe.s 55:
2116-2121
Gupta M, Fujimori A and Pommier Y (1995) Eukaryotic DNA topoisomerases 1.
Biochinii Bioplhxs Acta 1262: 1-14
Heymann E and Mentlein R (I1981) Carboxylesterases-amidases. MethodsEnzYvmol
77: 333-344
Jansen WJM, Zwart B, Hulscher STM, Giaccone G, Pinedo HM and Boven E (1997)
CPT- I1 in humnan colon-cancer cell lines and xenografts: characterization of
cellular sensitivity determinants. mstJ Con7cer 70: 335-340
C Cancer Research Campaign 1998 British Journal of Cancer (1998) 77(12), 2171-21762176 J van Ark-Otte et al
Jansen WJM, Hulscher TM, Van Ark-Otte J, Giaccone G, Pinedo HM and Boven E
(1998) CPT-I I sensitivity in relation to the expression ofP170-glycoprotein
and multidrug resistance-associated protein. BrJ Cancer 77: 359-365
Kaneda N, Nagata H, Furuta T and Yokokura T (1990) Metabolism and
pharmacokinetics ofthe camptothecin analogue CPT-11 in the mouse. Cancer
Res 50: 1715-1720
Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara
Y, Liu LF and Saijo N (1990) Establishment of a camptothecin analogue (CPT-
I I)-resistant cell line of human non-small cell lung cancer: characterization and
mechanism ofresistance. Cancer Res 50: 5919-5924
Kanzawa F, Nishio K, Kubota N and Saijo N (1995) Antitumor activities of a new
indolocarbazole substrate, NB-506, and establishment ofNB-506-resistant cell
lines, SBC-3/NB. Cancer Res 55: 2806-2813
Kasahara K, Fijiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T and Saijo N
(1992). Determinants of response to the DNA topoisomerase II inhibitors
doxorubicin and etoposide in human lung cancer cell lines. JNatl Cancer Inst
84:113-118
Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K (1991) Intracellular roles of
SN-38, a metabolite ofthe camptothecin derivative CPT-11, in the antitumor
effect ofCPT-1. Cancer Res 51: 4187-4191
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and
Borst P (1997) Analysis ofexpression ofcMOAT (MRP2), MRP3, MRP4, and
MRP5, homologues ofthe multidrug resistance-associated protein gene
(MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547
Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL,
Lankelma J and Pinedo HM (1990) Drug transport variants without p-
glycoprotein overexpression from a human squamous lung cancer cell line after
selection with doxorubucin. J Cell Pharmacol 1: 35-41
Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine JL,
Ihde DC, Kayser K and Gazdar AF (1989) MDRl gene expression in lung
cancer. JNatl Cancer Inst 81: 1144-1150
Liu L (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem
58: 351-375
Mattem MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL and Johnson RK
(1993) In vitro and in vivo effects ofclinically important camptothecin
analogues on multidrug-resistant cells. Oncol Res 5: 467-474
Nagai S, Yamauchi M, Andoh T, Nishizawa M, Satta T, Kodera Y, Kondou K,
Akiyama S, Ito K and Takagi H (1995) Establishment and characterization of
human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative
ofcamptothecin). JSurg Oncol 59: 116-124
Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima
Y and Saijo N (1992) Mechanism ofcross-resistance to a camptothecin
analogue (CPT-l 1) in a human ovarian cancer cell line selected by cisplatin.
Cancer Res 52: 328-333
Perego P, Capranico G, Supino R and Zunino F (1994) Topoisomerase I gene
expression and cell sensitivity to camptothecin in human cell lines ofdifferent
tumor types. Anti-Cancer Drugs 5: 645-649
Pizao PE, Smitskamp-Wilms E, van Ark-Otte J, Beijnen JH, Peters GJ, Pinedo HM
and Giaccone G (1994) Antiproliferative activity ofthe topoisomerase I
inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell
cultures. Biochem Pharnacol 48: 1145-1154
Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer
Res 54: 1431-1439
Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T-L,
Rock MK and Donehower RC (1994) Phase I and pharmacological study of the
novel topoisomerase I inhibitor 7-ethyl-10-[4-( 1-piperidino)- l-piperidino)-
carbonyloxycamptothecin (CPT- 1) administered as a ninety-minute infusion
every 3 weeks. Cancer Res 54: 427-436
Savaraj N, Xu R, Landy H, Lai SH, Stemau L, Solomon J, Wu CJ, Lampidis T and
Feun LG (1997) Comparison oftopoisomerase I and II expression in primary
brain tumor and lung cancer. Oncol Rep 4: 857-861
Senter PD, Marquardt H, Thomas BA, Hammock BD, Frank IS and Svensson HP
(1996) The role of rat serum carboxylesterase in the activation ofpaclitaxel and
camptothecin prodrugs. Cancer Res 56: 1471-1474
Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH (1993) The
current status ofcamptothecin analogues as antitumor agents. JNatl Cancer
Inst 85: 271-291
Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T and Tsuru D (1991) CPT- 11
converting enzyme from rat serum: purification and some properties.
J Pharmacobio-Dyn 14: 341-349
Whitehead TP, Kricka LJ, Carter TJ and Thorpe GH (1979) Analytical
luminescence: its potential in the clinical laboratory Clin Chem 25:
1531-1546
Yang C-HJ, Horton JK, Cowan KH and Schneider E (1995) Cross-resistance to
camptothecin analogues in a mitoxantrone-resistant human breast carcinoma
cell line is not due to DNA topoisomerase I. Cantcer Res 55: 4004-4009
Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, De Haas M, Smith AJ,
Broxterman HJ, Mulder NH, De Vries EGE, Baas F and Borst P (1993)
Analysis ofthe expression of MRP, the gene for a new putative transmembrane
drug transporter, in human multidrug resistant lung cancer cell lines. Cancer
Res 53: 1747-1750
Zijlstra JG, De Vries EGE and Mulder NH (1987) Multifactorial drug resistance in
an adriamycin-resistant human small cell lung cancer carcinoma cell line.
CancerRes 47: 1780-1784
British Journal ofCancer (1998) 77(12), 2171-2176 C Cancer Research Campaign 1998